<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV)-positive Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and EBV-infected B cells elicit humoral factors that inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-induced <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, resulting in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> and regression </plain></SENT>
<SENT sid="1" pm="."><plain>Of the chemokine factors identified in association with this growth behavior, none have induced complete <z:mp ids='MP_0010537'>tumor regression</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously identified tissue inhibitors of metalloproteinase (TIMP)-1 in various B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Here we show that induction of TIMP-1 expression in an EBV-negative Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line results in a biphasic, in vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> pattern in the <z:mp ids='MP_0003815'>nude</z:mp> mouse that is essentially identical to EBV-positive Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>The initial effect of TIMP-1 is to enhance <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, consistent with the reported anti-apoptotic effect of TIMP-1 on B cell growth </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> and regression then follow the initial period of rapid, increased <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Only microscopic foci of residual, proliferating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells are observed on biopsy of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site </plain></SENT>
<SENT sid="7" pm="."><plain>This latter effect is mediated by TIMP-1 inhibition of an angiogenic response within the developing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass, as demonstrated by immunostaining and microvessel counts </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that TIMP-1 is an important mediator of the in vivo growth properties of EBV-positive Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>